Related Experiment Video
Updated: May 23, 2026
Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus (MRSA)
Published on: February 9, 2011
Managing Severe Community-Acquired Pneumonia Due to Community Methicillin-Resistant Staphylococcus aureus (MRSA)
Jason C Kwong1, Kyra Chua, Patrick G P Charles
1Department of Infectious Diseases, Austin Health, 145 Studley Road, PO Box 5555, Heidelberg, Victoria, 3084, Australia, jason.kwong@austin.org.au.
Abstract:
Community-associated methicillin-resistant Staphylococcus aureus (MRSA) is a rare, but significant cause of community-acquired pneumonia (CAP). A number of virulence determinants have been implicated in the development of severe community MRSA pneumonia, characterized by multilobar cavitating necrosis in patients without usual risk-factors for pneumonia. Optimal management is uncertain, and is extrapolated from anecdotal experiences with small case series, randomized studies of hospital-acquired pneumonia, and laboratory investigations using in vitro experiments and animal models of MRSA pneumonia. Adequate clinical suspicion, early diagnosis and administration of appropriate antibiotics are necessary for best patient outcomes, although some patients will still do badly even with early anti-MRSA therapy. Vancomycin or linezolid have been recommended as first-line therapy, possibly in combination with other antibiotics. Newer antibiotics such as ceftaroline are still being evaluated.
Insights
Community-associated methicillin-resistant Staphylococcus aureus (MRSA) causes severe pneumonia. Early diagnosis and appropriate antibiotics like vancomycin or linezolid are crucial, though outcomes vary.
Area of Science:
- Infectious Diseases
- Pulmonology
- Microbiology
Background:
- Community-associated methicillin-resistant Staphylococcus aureus (MRSA) is an infrequent but serious cause of community-acquired pneumonia (CAP).
- Severe MRSA pneumonia presents with multilobar cavitating necrosis, often in patients lacking typical pneumonia risk factors.
- Virulence factors contributing to severe MRSA pneumonia are under investigation.
Purpose of the Study:
- To review the current understanding of severe community-associated MRSA pneumonia.
- To discuss diagnostic and management strategies for this condition.
Main Methods:
- Literature review of case series, clinical studies, and laboratory investigations.
- Extrapolation of management strategies from hospital-acquired pneumonia and in vitro/animal models.
- Analysis of recommended first-line therapies and emerging treatment options.
Main Results:
- Optimal management for severe MRSA pneumonia remains uncertain.
- Early diagnosis and appropriate antibiotic administration are vital for patient outcomes.
- Vancomycin and linezolid are recommended first-line agents, potentially with combination therapy.
Conclusions:
- Despite prompt treatment, some patients with severe MRSA pneumonia experience poor outcomes.
- Ceftaroline is an emerging antibiotic option currently under evaluation for MRSA pneumonia.
- Further research is needed to optimize treatment protocols for severe community-associated MRSA pneumonia.
Related Concept Videos
01:25Clinical Significance of Antibiotic Resistance
01:25Mechanism of Antibiotic Resistance in MRSA
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
01:29Staphylococcal Skin Infections